Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody
Open accessThe DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Abstract
Despite promising results in the use of anti-epidermal growth factor receptor (EGFR) Abs for cancer therapy, several issues remain to be addressed. An increasing emphasis is being placed on immune effector mechanisms. It has become clear for other Abs directed to tumor targets that their effects involve the adaptive immunity, mainly by the contribution of Fc region-mediated mechanisms. Given the relevance of EGFR signaling for tumor biology, we wonder whether the oncogene inhibition could contribute to Ab-induced vaccine effect. In a mouse model in which 7A7 (an anti-murine EGFR Ab) and AG1478 (an EGFR-tyrosine kinase inhibitor) displayed potent antimetastatic activities, depletion experiments revealed that only in the case of the Ab, the effect was dependent on CD4(+) and CD8(+) T cells. Correspondingly, 7A7 administration elicited a remarkable tumor-specific CTL response in hosts. Importantly, experiments using 7A7 F(ab')(2) suggested that in vivo Ab-mediated EGFR blockade may play an important role in the linkage with adaptive immunity. Addressing the possible mechanism involved in this effect, we found quantitative and qualitative differences between 7A7 and AG1478-induced apoptosis. EGFR blocking by 7A7 not only prompted a higher proapoptotic effect on tumor metastases compared with AG1478, but also was able to induce apoptosis with immunogenic potential in an Fc-independent manner. As expected, 7A7 but not AG1478 stimulated exposure of danger signals on tumor cells. Subcutaneous injection of 7A7-treated tumor cells induced an antitumor immune response. This is the first report, to our knowledge, of a tumor-specific CTL response generated by Ab-mediated EGFR inhibition, suggesting an important contribution of immunogenic apoptosis to this effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At least in part, this reflects the ability of EGFR-targeted agents to induce ICD (Garrido et al., 2011; Pozzi et al., 2016) (Box 1) and the consequent exposure of the ''eat-me'' signal calreticulin (CALR) coupled to the downregulation of the ''don't eat me'' signal CD47 on the surface of malignant cells (Nigro et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Garrido et al., 2011
In the citing paper
“DAMPemission by lung cancer cells, linked to DC maturation in vitro”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Garrido et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
Albert, M. L., Sauter, B., & Bhardwaj, N. (1998) · Nature · doi:10.1038/32183 · Cited by 2,349
SYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H. G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,314
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
How dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
Corpse clearance defines the meaning of cell death
Savill, J., & Fadok, V. (2000) · Nature · doi:10.1038/35037722 · Cited by 1,547
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Immunogenic and tolerogenic cell death
Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Autophagy Gene-Dependent Clearance of Apoptotic Cells during Embryonic Development
Qu, X., Zou, Z., Sun, Q., Luby-Phelps, K., Cheng, P., Hogan, R. N., Gilpin, C., & Levine, B. (2007) · Cell · doi:10.1016/j.cell.2006.12.044 · Cited by 653
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
Shaping and reshaping CD8+ T-cell memory
Harty, J. T., & Badovinac, V. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2251 · Cited by 555
What is trogocytosis and what is its purpose?
Joly, E., & Hudrisier, D. (2003) · Nature Immunology · doi:10.1038/ni0903-815 · Cited by 543
Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Garg, A. D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D. V., & Agostinis, P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.003 · Cited by 496
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Molecular characteristics of immunogenic cancer cell death
Tesniere, A., Panaretakis, T., Kepp, O., Apetoh, L., Ghiringhelli, F., Zitvogel, L., & Kroemer, G. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402269 · Cited by 494
Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity
Weihua, Z., Tsan, R., Huang, W.-C., Wu, Q., Chiu, C.-H., Fidler, I. J., & Hung, M.-C. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.015 · Cited by 490
Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482
Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474
Structure-Based View of Epidermal Growth Factor Receptor Regulation
Ferguson, K. M. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125829 · Cited by 368
MATZINGER, P. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb03118.x · Cited by 359
Janmaat, M. L., Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2003) · PubMed · Cited by 356
Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011097 · Cited by 349
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
Martinelli, E., De Palma, R., Orditura, M., De Vita, F., & Ciardiello, F. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03992.x · Cited by 333
Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.
Covell, D. G., Barbet, J., Holton, O. D., BLACK, C. D. V., Parker, R. J., & Weinstein, J. N. (1986) · PubMed · Cited by 311
Efficient Cross-presentation Depends on Autophagy in Tumor Cells
Li, Y., Wang, L.-X., Yang, G., Hao, F., Urba, W. J., & Hu, H.-M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0161 · Cited by 303
Fan, Z., Masui, H., Altas, I., & Mendelsohn, J. M. (1993) · PubMed · Cited by 271
CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma
Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., & Eisenbach, L. (1994) · Nature · doi:10.1038/369067a0 · Cited by 254
Yrlid, U., & Wick, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.613 · Cited by 244
Schneider-Merck, T., Lammerts van Bueren, J. J., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 222
Gilmore, A. P., Valentijn, A. J., Wang, P., Ranger, A. M., Bundred, N., O'Hare, M. J., Wakeling, A., Korsmeyer, S. J., & Streuli, C. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108863200 · Cited by 207
Manning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205
Ecto‐calreticulin in immunogenic chemotherapy
Obeid, M., Tesniere, A., Panaretakis, T., Tufi, R., Joza, N., Van Endert, P., Ghiringhelli, F., Apetoh, L., Chaput, N., Flament, C., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00567.x · Cited by 202
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Abès, R., Gélizé, E., Fridman, W. H., & Teillaud, J.-L. (2010) · Blood · doi:10.1182/blood-2009-10-248609 · Cited by 198
Crombet, T., Figueredo, J., Catalá, M., Sandra, G., Selva, J. C., Cruz, T., Toledo, C., Silva, S., Pestano, Y., Ramos, M., et al. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.4.2522 · Cited by 171
Self-citationLópez-Albaitero, A., Lee, S. C., Morgan, S., Grandis, J. R., Gooding, W. E., Ferrone, S., & Ferris, R. L. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0697-4 · Cited by 160
Lee, S. C., Srivastava, R. M., López-Albaitero, A., Ferrone, S., & Ferris, R. L. (2011) · Immunologic Research · doi:10.1007/s12026-011-8231-0 · Cited by 156
Hilchey, S. P., Hyrien, O., Mosmann, T. R., Livingstone, A. M., Friedberg, J. W., Young, F., Fisher, R. I., Kelleher, R. J., Bankert, R. B., & Bernstein, S. H. (2009) · Blood · doi:10.1182/blood-2008-10-185280 · Cited by 151
Immune Response Against Dying Tumor Cells
Zitvogel, L., Casares, N., Péquignot, M. O., Chaput, N., Albert, M. L., & Kroemer, G. (2004) · Advances in immunology · doi:10.1016/s0065-2776(04)84004-5 · Cited by 149
Selenko-Gebauer, N., Majdic, O., Draxler, S., Berer, A., Jaeger, U., Knapp, W., & Stöckl, J. (2001) · Leukemia · doi:10.1038/sj.leu.2402226 · Cited by 139
Mellén, M., de la Rosa, E. J., & Boya, P. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.40 · Cited by 129
(2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1201 · Cited by 127
Srivastava, P. K. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.009 · Cited by 123
Shepard, H. M., Brdlik, C. M., & Schreiber, H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36049 · Cited by 109
Eisenbach, L., Hollander, N., Greenfeld, L., Yakor, H., Segal, S., & Feldman, M. (1984) · International Journal of Cancer · doi:10.1002/ijc.2910340421 · Cited by 108
Beum, P. V., Mack, D. A., Pawluczkowycz, A. W., Lindorfer, M. A., & Taylor, R. P. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8120 · Cited by 94
Spiridon, C. I., Guinn, S., & Vitetta, E. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0549 · Cited by 88
Ellis, A. G., Doherty, M. M., Walker, F., Weinstock, J., Nerrie, M., Vitali, A., Murphy, R., Johns, T. G., Scott, A. M., Levitzki, A., et al. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.01.020 · Cited by 85
Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Gabrilovich, D., & Pisarev, V. (2003) · Current Drug Targets · doi:10.2174/1389450033490849 · Cited by 72
Real, P. J., Benito, A., Cuevas, J., Berciano, M. T., de Juan, A., Coffer, P., Gomez-Roman, J., Lafarga, M., Lopez-Vega, J. M., & Fernandez-Luna, J. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1134 · Cited by 72
Crombet, T., Torres, O., Rodríguez, V., Menéndez, A., Stevenson, A., Ramos, M., Torres, F., Figueredo, R., Veitía, I., Iznaga, N., et al. (2001) · Hybridoma · doi:10.1089/02724570152057634 · Cited by 58
Self-citationEpidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy
Pal, S. K., & Pegram, M. D. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200506000-00003 · Cited by 52
Garrido, G., Lorenzano, P., Sánchez, B., Beausoleil, I., Alonso, D. F., Pérez, R., & Fernandez, L. E. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0313-4 · Cited by 48
Self-citationWatanabe, T., Kawamura, T., Kawamura, H., Haga, M., Shirai, K., Watanabe, H., Eguchi, S., & Abo, T. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.12.5805 · Cited by 35
Iivanainen, E., Lauttia, S., Zhang, N., Tvorogov, D., Kulmala, J., Grenman, R., Salven, P., & Elenius, K. (2009) · Microvascular Research · doi:10.1016/j.mvr.2009.06.010 · Cited by 34
7A7 MAb: A New Tool for the Pre-Clinical Evaluation of EGFR-Based Therapies
Garrido, G., Sanchez, B., Rodriguez, H. M., Lorenzano, P., Alonso, D. F., & Fernandez, L. E. (2004) · Hybridoma and Hybridomics · doi:10.1089/1536859041224280 · Cited by 24
Self-citationPorgador, A., Brenner, B., Vadai, E., Feldman, M., & Eisenbach, L. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910470713 · Cited by 23
High levels of apoptosis are associated with improved survival in non-small cell lung cancer.
Macluskey, M., Baillie, R., Chandrachud, L. M., Pendleton, N., & Schor, A. M. (2000) · PubMed · Cited by 16
In vivo cytotoxic T-lymphocyte induction may take place via CD8+ T helper lymphocytes
Lasarte, J. J., Sarobe, P., Prìeto, J., & Borrás‐Cuesta, F. (1995) · Research in Immunology · doi:10.1016/0923-2494(96)80238-0 · Cited by 11
Research works printed but not linked: 2
- Baselga, J., R. Herbst, P. LoRusso, D. Rischin, M. Ranson, R. Plummer, E. Raymond, A.-M. Maddox, S. Kaye, D. Kieback, et al. 2000. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor re- ceptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tu- mor types: evidence of activity and good tolerability. Proc. Am. Soc. Clin. Oncol. 19: 2000.
- Liu, B., M. Fang, M. Schmidt, Y. Lu, J. Mendelsohn, and Z. Fan. 2000. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br. J. Cancer 82: 1991-1999.
Cited by
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Metadata
- Authors
- Garrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E.
- Affiliations
- Center of Molecular Immunology (Cuba) (CU)
- Quality Control Department, Quality Direction, Center of Molecular Immunology , Havana 11600 ,
- Tumor Immunology Direction, Molecular Immunology Institute, Center of Molecular Immunology , Havana 11600 ,
- Innovative Direction, Molecular Immunology Institute, Center of Molecular Immunology , Havana 11600 ,
- Corresponding author
- Garrido, Greta
- Rabasa, Ailem
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 187
- Issue
- 10
- Pages
- 4954-4966
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2144107170
- Cited by
- 91
- References
- 64
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 8 · 2022: 5 · 2021: 8 · 2020: 10 · 2019: 8 · 2018: 8 · 2017: 4 · 2016: 2 · 2015: 9 · 2014: 9 · 2013: 9 · 2012: 6
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- epidermal growth factor receptor, anti-EGFR monoclonal antibody, AG1478, EGFR tyrosine kinase inhibitors, tumor-specific cytotoxic T lymphocytes, metastasis, adaptive immunity, damage-associated molecular patterns, antitumor immunity, CD4 and CD8 T cells
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody Specificity, Cells, Cultured, Female, Immunoglobulin Fc Fragments, Lung Neoplasms, Melanoma, Experimental, Mice, Inbred C57BL, T-Lymphocytes, Cytotoxic, Apoptosis, Carcinoma, Lewis Lung, Antibodies, Blocking, Cell Line, Tumor, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.